• Explore /
  • Poster
  • / A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.

A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Johanna C. Bendell , Uwe Pelzer , Mark S. Womack IV, Erkut Hasan Borazanci , Nathan Bahary , Ignacio Garrido-Laguna , Michela Maur , Tyler Prater , Donna Elise Levy , Damien Cronier , Sam Ramage , Teresa Macarulla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Prevention, Diagnosis, and Screening

Clinical Trial Registration Number

NCT03086369

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS524)

DOI

10.1200/JCO.2018.36.4_suppl.TPS524

Abstract #

TPS524

Poster Bd #

P24

Abstract Disclosures

Similar Posters

First Author: Uwe Pelzer

First Author: Daniel John Renouf

First Author: Elisa Giommoni

First Author: Benedikt Westphalen